Tandem Diabetes Care, Inc. (TNDM) FY2026 YTD Q2 Statement of Cash Flows

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
Tandem Diabetes Care, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from issuance of convertible senior notes due 2032, net of $8,843 debt issuance costs → financing reconciliation: $291,157,000.00Cash used to settle withholding taxes on vested restricted stock, net of proceeds from issuance of common stock under Company stock plans → financing reconciliation: $458,000.00financing reconciliation → Net cash from financing activities: $276,315,000.00financing reconciliation → Payment for capped call transactions related to convertible senior notes due 2032: $15,300,000.00Proceeds from maturities and redemptions of short-term investments → investing reconciliation: $69,473,000.00investing reconciliation → Purchases of short-term investments: $260,512,000.00investing reconciliation → Purchases of equity investments, strategic investments, and intangible assets: $81,427,000.00investing reconciliation → Purchases of property and equipment: $10,318,000.00Net cash used in operating activities → operating reconciliation: $23,576,000.00Stock-based compensation expense → operating reconciliation: $31,400,000.00Accounts payable → operating reconciliation: $23,500,000.00Loss from equity method investment → operating reconciliation: $9,506,000.00Depreciation and amortization expense → operating reconciliation: $8,974,000.00Provision for expected credit losses → operating reconciliation: $5,358,000.00Operating leases and other current liabilities → operating reconciliation: $4,095,000.00Amortization of debt issuance costs → operating reconciliation: $1,384,000.00Other → operating reconciliation: $1,005,000.00operating reconciliation → Net loss: $41,561,000.00operating reconciliation → Prepaid and other current assets: $18,502,000.00operating reconciliation → Employee-related liabilities: $17,072,000.00operating reconciliation → Other long-term assets: $11,134,000.00operating reconciliation → Inventories: $8,564,000.00operating reconciliation → Deferred revenue: $3,782,000.00operating reconciliation → Other long-term liabilities: $3,280,000.00operating reconciliation → Accounts receivable, net: $3,082,000.00operating reconciliation → Amortization of discount or (accretion of premium) on short-term investments: $1,821,000.00Net cash used in investing activities → investing reconciliation: $282,784,000.00Exchange-rate effect → Cash sources and uses: $2,229,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $90,634,000.00Net cash from financing activities → Cash sources and uses: $276,315,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $62,818,000.00Cash sources and uses → Net cash used in investing activities: $282,784,000.00Cash sources and uses → Net cash used in operating activities: $23,576,000.00Net loss: -$41,561,000.00Net loss−$41.56 MDepreciation and amortization expense: $8,974,000.00Depreciation & amortization+$8.97 MAmortization of debt issuance costs: $1,384,000.00Debt issuance cost amortization+$1.38 MProvision for expected credit losses: $5,358,000.00Credit loss provision+$5.36 MOperating lease and other impairment charges: $0.00Amortization of discount or (accretion of premium) on short-term investments: -$1,821,000.00Securities accretion, net−$1.82 MLoss from equity method investment: $9,506,000.00Equity-method results+$9.51 MStock-based compensation expense: $31,400,000.00Stock-based compensation+$31.40 MAcquired in-process research and development expenses: $0.00Other: $1,005,000.00Other operating, net+$1.01 MAccounts receivable, net: -$3,082,000.00Accounts receivable−$3.08 MInventories: -$8,564,000.00Inventories−$8.56 MPrepaid and other current assets: -$18,502,000.00Prepaid & other assets−$18.50 MOther long-term assets: -$11,134,000.00Other noncurrent assets−$11.13 MAccounts payable: $23,500,000.00Accounts payable+$23.50 MEmployee-related liabilities: -$17,072,000.00Accrued compensation−$17.07 MDeferred revenue: -$3,782,000.00Deferred revenue−$3.78 MOperating leases and other current liabilities: $4,095,000.00Operating lease liabilities+$4.10 MOther long-term liabilities: -$3,280,000.00Other noncurrent liabilities−$3.28 MNet cash used in operating activities: -$23,576,000.00. Cash required to fund net payments.Operating cash−$23.58 Moperating reconciliation: $108,798,000.00Proceeds from issuance of convertible senior notes due 2032, net of $8,843 debt issuance costs: $291,157,000.00Convertible debt issued+$291.16 MPrincipal payments on convertible senior notes due 2025: $0.00Payment for capped call transactions related to convertible senior notes due 2032: -$15,300,000.00Capped call purchases, 2032−$15.30 MCash used to settle withholding taxes on vested restricted stock, net of proceeds from issuance of common stock under Company stock plans: $458,000.00Stock award tax withholding, net+$458.00 KNet cash from financing activities: $276,315,000.00Financing cash+$276.32 Mfinancing reconciliation: $291,615,000.00Purchases of short-term investments: -$260,512,000.00Short-term investment purchases−$260.51 MProceeds from maturities and redemptions of short-term investments: $69,473,000.00Short-term investment maturities+$69.47 MPurchases of property and equipment: -$10,318,000.00PP&E purchases−$10.32 MAcquisition of in-process research and development: $0.00Purchases of equity investments, strategic investments, and intangible assets: -$81,427,000.00Strategic & intangible purchases−$81.43 MNet cash used in investing activities: -$282,784,000.00. Cash required to fund net payments.Investing cash−$282.78 Minvesting reconciliation: $352,257,000.00Cash sources and uses: $369,178,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $90,634,000.00Beginning cash$90.63 MEnding cash: Cash, cash equivalents, and restricted cash: $62,818,000.00Ending cash$62.82 MExchange-rate effect: $2,229,000.00FX effect+$2.23 MCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsNet loss −$41.56M + net operating adjustments $17.99M = operating cash −$23.58MFree cash flow−$33.89 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$27.82 MEnding cash − beginning cash
Chart details

Tandem Diabetes Care, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
90,634,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 23,576,000 US dollars. Net cash used.
Net loss
negative 41,561,000 US dollars
Depreciation and amortization expense
8,974,000 US dollars
Amortization of debt issuance costs
1,384,000 US dollars
Provision for expected credit losses
5,358,000 US dollars
Operating lease and other impairment charges
0 US dollars
Amortization of discount or (accretion of premium) on short-term investments
negative 1,821,000 US dollars
Loss from equity method investment
9,506,000 US dollars
Stock-based compensation expense
31,400,000 US dollars
Acquired in-process research and development expenses
0 US dollars
Other
1,005,000 US dollars
Accounts receivable, net
negative 3,082,000 US dollars
Inventories
negative 8,564,000 US dollars
Prepaid and other current assets
negative 18,502,000 US dollars
Other long-term assets
negative 11,134,000 US dollars
Accounts payable
23,500,000 US dollars
Employee-related liabilities
negative 17,072,000 US dollars
Deferred revenue
negative 3,782,000 US dollars
Operating leases and other current liabilities
4,095,000 US dollars
Other long-term liabilities
negative 3,280,000 US dollars
Investing activities
negative 282,784,000 US dollars. Net cash used.
Purchases of short-term investments
negative 260,512,000 US dollars
Proceeds from maturities and redemptions of short-term investments
69,473,000 US dollars
Purchases of property and equipment
negative 10,318,000 US dollars
Acquisition of in-process research and development
0 US dollars
Purchases of equity investments, strategic investments, and intangible assets
negative 81,427,000 US dollars
Financing activities
276,315,000 US dollars. Net cash provided.
Proceeds from issuance of convertible senior notes due 2032, net of $8,843 debt issuance costs
291,157,000 US dollars
Principal payments on convertible senior notes due 2025
0 US dollars
Payment for capped call transactions related to convertible senior notes due 2032
negative 15,300,000 US dollars
Cash used to settle withholding taxes on vested restricted stock, net of proceeds from issuance of common stock under Company stock plans
458,000 US dollars
Operating adjustment reconciliation
108,798,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
291,615,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
352,257,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
2,229,000 US dollars
Ending cash on Jun 30, 2026
62,818,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
369,178,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 27,816,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 23,576,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
10,318,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 33,894,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$41.56M + net operating adjustments $17.99M = operating cash −$23.58M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 23,576,000 US dollars minus 10,318,000 US dollars equals negative 33,894,000 US dollars.
Tandem Diabetes Care, Inc. (TNDM) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!